toosendanin has been researched along with Bone Loss, Perimenopausal in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, T; Ouyang, Z; Tan, T; Xiang, C | 1 |
1 other study(ies) available for toosendanin and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Toosendanin inhibits osteoclast formation and alleviate postmenopausal osteoporosis by regulating the p38 signaling pathway.
Topics: Animals; Bone Resorption; Cell Differentiation; Female; Humans; Mice; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; RANK Ligand; Signal Transduction | 2023 |